Accuray has received CE Mark approval for its CT-guided helical radiotherapy system, Accuray Helix.

The system aims to address the scarcity of linear accelerators in emerging markets where such resources are limited, particularly outside urban areas.

Accuray Helix is claimed to be engineered to provide high-performance and high-throughput radiotherapy treatments.

The system's versatility is expected to enhance patient care personalisation while increasing clinic productivity by enabling the treatment of more patients each day.

The Accuray Helix system is tailored to deliver precise, targeted radiation treatments for a variety of cancers, including those affecting the breast, cervix, gastrointestinal tract, head and neck, lung, and prostate.

Accuray president and CEO Suzanne Winter said that even though the demand for cancer services is increasing globally, there are some areas in the world where there are greater gaps in access to radiation medicine.

Winter commented: “India is a priority due to this disparity as there is a significant deficit in the availability of radiation therapy systems compared to the size of its population and incidence of cancer. Our goal with the introduction of Accuray Helix is to close some of these gaps to patient access with our comprehensive solutions.”

According to Winter, the Accuray Helix system blends affordability with automation and tools to improve the speed of planning and delivery of radiation.

Winter added: “We believe it will enable a broader range of capabilities for facilities that may have resources and staffing for only one system, enabling them to offer state-of-the-art cancer care in their communities.”

In June 2024, Accuray secured the Chinese National Medical Products Administration’s approval for its Accuray Precision treatment planning system.